Uptake of human papillomavirus vaccine stalls in the USBMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f4798 (Published 29 July 2013) Cite this as: BMJ 2013;347:f4798
- Michael McCarthy
The proportion of teenage girls in the United States receiving the vaccine against human papillomavirus (HPV) appears to have stalled at a little over 50%, the US Centers for Disease Control and Prevention has reported.1
The report, which appears in the current issue of the CDC’s Morbidity and Mortality Weekly Report, said that from 2007 to 2011 the percentage of girls in the US, aged 13-17 years, who had received at least one of the three recommended doses of the vaccine doubled from 25.1% to 53%, but, then, uptake appeared to stall, increasing to just 53.8% in 2012.
At a press conference to announce …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial